Hepatitis C and hepatocellular carcinoma.

Area of Science:

• Hepatology
• Oncology
• Virology

Background:

• Chronic hepatitis C virus (HCV) infection is a significant cause of hepatocellular carcinoma (HCC), particularly in the United States.
• Cirrhosis or advanced fibrosis is a primary risk factor for HCC development.
• Current surveillance for patients with cirrhosis includes alpha-fetoprotein and ultrasound.

Purpose of the Study:

• To review the management of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection.
• To discuss the limitations and indications for surgical resection and liver transplantation for HCC.
• To evaluate the efficacy of various therapeutic modalities for HCC in the context of HCV.

Main Methods:

• Literature review of studies on HCC management in HCV-infected patients.
• Analysis of treatment outcomes for surgical resection, liver transplantation, and other therapies.
• Evaluation of risk factors and surveillance strategies for HCC in HCV cirrhosis.

Main Results:

• Resection is feasible for HCC in well-compensated cirrhosis (Child's A) with specific tumor characteristics.
• Liver transplantation offers the best definitive treatment for select HCV-infected patients with early-stage HCC.
• Chemoembolization, ablation, systemic chemotherapy, and hormonal therapy generally lack survival benefits as primary treatments, though some combinations show promise.

Conclusions:

• Liver transplantation is the preferred curative option for eligible HCV-related HCC patients.
• Surgical resection for HCC is restricted to patients with compensated cirrhosis and early-stage disease.
• Further research is needed to explore the role of locoregional therapies as bridge treatments to transplantation.